Recent breakthroughs are fundamentally recasting our understanding of cancer, shifting the focus from a disease of uncontrolled cell division to one characterized by a profoundly altered and ravenous metabolism. At the heart of this new perspective is the discovery that malignant cells harbor a
The treatment paradigm for bladder cancer is undergoing a seismic shift, as a new wave of clinical research moves beyond traditional protocols to pioneer a more integrated, intelligent, and immune-focused approach to care. This evolution is not merely about refining existing methods but about
Today we’re joined by Ivan Kairatov, a biopharma expert with deep experience in drug development and the intricate dance between innovation, regulation, and market perception. We'll be dissecting the recent developments with Intellia Therapeutics, a pioneer in CRISPR gene editing. The company has
Within the intricate ecosystem of a tumor, cancer cells are far from acting alone; they are surrounded by a complex network of supporting cells that form the tumor microenvironment. Among these collaborators, cancer-associated fibroblasts (CAFs) have emerged as particularly influential players.
The global surge in metabolic diseases presents one of the most significant public health challenges of our time, with conditions like diabetes affecting more than one in five adults in certain regions, such as the Middle East. This escalating crisis has traditionally been met with a reactive
Biopharma expert Ivan Kairatov joins us today to discuss a paradigm shift in evaluating cutaneous chronic graft-versus-host disease (cGVHD), a severe complication of stem cell transplantation. Drawing from his work with an international NIH task force, he explains why current assessment standards
